Opko Health

Sector: Healthcare & Life Sciences

opko.com

About Opko Health

OPKO Health, Inc. (OPK) Skip to main content Skip to footer Careers News & Media Contact Therapies Overview Ngenla Rayaldee Research Overview Pipeline Publications Scientific Presentations Diagnostics Company Overview Leadership Locations Partnerships Investors Overview News / Events Presentations Company Info Financial Info Stock Data SEC Filings Governance Careers News & Media Contact OPKO Healt

Products

  • Products: Ngenla.
  • Rayaldee.
  • NGENLA™ (somatrogon-ghla).
  • is approved by the U.S. Food and Drug Administration as a once-weekly.
  • human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA™ is poised to transform the human growth hormone treatment landscape by offering patients next-generation innovation.
  • RAYALDEE® is an extended-release (ER) oral formulation of calcifediol.
  • a prohormone of calcitriol.
  • the active form of vitamin D3. The product is the first and only medicine approved by the U.S. Food and Drug Administration for raising serum total 25D and lowering blood levels of intact parathyroid hormone (iPTH). RAYALDEE is approved to treat SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency in the U.S. and in 11 European countries.
  • url: https://www.opko.com/therapies.

Latest Company Updates